Yield10 Bioscience

Yield10 Bioscience, Inc. operates as an agricultural bioscience company. It focuses on the development of technologies to produce step-change improvements in crop yield for food and feed crops to enhance global food security. The company was founded by Anthony J. Sinskey, Simon F. Williams and Oliver P. Peoples in June 1992 and is headquartered in Woburn, MA.

Earnings data Q1 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Yield10 Bioscience, Inc. is an agricultural bioscience company, which engages in the development of oilseed Camelina sativa as a platform crop for large scale production of low carbon sustainable seed products. The company was founded by Anthony J. Sinskey, Simon F. Williams, and Oliver P. Peoples in 1992 and is headquartered in Woburn, MA.

Yield10 Bioscience, Inc. (YTEN) Q4 2023 Earnings Call Transcript

-Granted global commercial license to Vision Bioenergy for Camelina addressing the biofuel market -Advanced regulatory and seed scale-up program for omega-3 Camelina -E3902 oil trait in Camelina cleared by regulatory authority for planting in Canada -Management will host a conference call today at 4:30 p.m. (ET) to review  financial results and provide a corporate update

Yield10 Bioscience Announces Fourth Quarter and Full Year 2023 Financial Results

WOBURN, Mass., March 28, 2024 (GLOBE NEWSWIRE) -- Yield10 Bioscience, Inc. (Nasdaq:YTEN) (“Yield10” or the “Company”), an agricultural bioscience company, today announced that the Company will report its fourth quarter and full year 2023 financial results and provide a corporate update on Monday, April 1, 2024.

Yield10 Bioscience to Announce Fourth Quarter and Full Year 2023 Financial Results and Host a Conference Call on Monday, April 1, 2024

WOBURN, Mass., March 26, 2024 (GLOBE NEWSWIRE) -- Yield10 Bioscience, Inc. (Nasdaq:YTEN) (“Yield10” or the “Company”), an agricultural bioscience company, today reported that the Plant Biosafety Office (“PBO”) of the Canadian Food Inspection Agency (“CFIA”) recently reviewed information on the Company's E3902 Camelina sativa (“Camelina”) and determined that E3902 is not a Plant with Novel Trait (PNT) and is not subject to a pre-market notification under Part V of the Seeds Regulations. Yield10's E3902 Camelina combines genome edits in three proprietary genetic traits, C3008a, C3008b and C3009, that result in an increase in oil production by five percent and produce a lighter seed coat color as compared to the parental Camelina line. E3902 Camelina remains subject to other applicable requirements of the Seeds Act and Regulations in Canada.

Yield10 Bioscience Announces that the Plant Biosafety Office of the Canadian Food Inspection Agency has Cleared Genome-edited E3902 Camelina for Planting in Canada

Yield10 Bioscience (NASDAQ: YTEN ) stock is rocketing higher on Thursday after the agricultural bioscience company got new approval from the Department of Agriculture's (USDA) Biotechnology Regulatory Services (BRS). The big news here is Yield10 Bioscience's Camelina sativa varieties getting approval for breeding and growth in the U.S. This came after the agency determined the genetically modified plants don't fall under regulations 7 CFR part 340.

Why Is Yield10 (YTEN) Stock Up 117% Today?

Yield10 Bioscience achieves significant milestone enabling ramp-up to commercial scale production of omega-3 fatty acids in Camelina in the United States.

USDA-APHIS Determines that Yield10 Bioscience's Omega-3 Camelina Varieties May Be Planted and Bred in the United States

-Herbicide tolerance is critical to planting the Camelina crop on large acreage for the biofuel and omega-3 oil markets -Herbicide tolerance is critical to planting the Camelina crop on large acreage for the biofuel and omega-3 oil markets

Yield10 Bioscience Reports that Proprietary Varieties of Winter Camelina Show Tolerance to Commonly Used Herbicides in First Field Tests

Global License of Industry-Leading Elite Herbicide Tolerant Camelina Accelerates Biofuel Feedstock Production Global License of Industry-Leading Elite Herbicide Tolerant Camelina Accelerates Biofuel Feedstock Production

Yield10 Bioscience Grants Global License to VISION Bioenergy Oilseeds for Herbicide Tolerant Camelina Cultivated for the Production of Biofuel Feedstock

-Prioritizes Activities to Advance Omega-3 Camelina Program in 2024 -Reports Completion of Contra Season Production of Omega-3 Camelina Seed in Chile - Company also Provides Update on Nasdaq Status - WOBURN, Mass., Feb. 07, 2024 (GLOBE NEWSWIRE) -- Yield10 Bioscience, Inc. (Nasdaq:YTEN) (“Yield10” or the “Company”), an agricultural bioscience company, today provided an update on its Omega-3 Camelina program.

Yield10 Bioscience Provides an Update on its Omega-3 Camelina Program

Yield10 Bioscience (NASDAQ: YTEN ) stock is rocketing higher on Monday despite a lack of news from the U.S. agricultural bioscience company. This rally comes alongside heavy trading of YTEN stock on Monday morning.

Why Is Yield10 Bioscience (YTEN) Stock Up 34% Today?

WOBURN, Mass., Jan. 08, 2024 (GLOBE NEWSWIRE) -- Yield10 Bioscience, Inc. (Nasdaq:YTEN) (“Yield10” or the “Company”), an agricultural bioscience company, today announced that the Company recently filed a request for a Regulatory Status Review (“RSR”) with USDA-APHIS Biotechnology Regulatory Services (“BRS”) under the Sustainable, Ecological, Consistent, Uniform, Responsible, Efficient (“SECURE”) Rule for proprietary elite Camelina sativa ("Camelina”) varieties designed to produce seed oil containing both essential omega-3 fatty acids eicosapentaenoic acid (“EPA”) and docosahexaenoic acid (“DHA”).

Yield10 Bioscience Files Request for Regulatory Status Review with USDA-APHIS for Camelina Designed to Produce the EPA and DHA Components of Omega-3 Oil

-Herbicide Technology Critical to Enabling Large-Acreage Adoption of Camelina in North America -Herbicide Technology Critical to Enabling Large-Acreage Adoption of Camelina in North America

USDA-APHIS Determines that Yield10 Bioscience's Stacked Herbicide Tolerant Camelina May Be Planted and Bred in the United States

-Yield10 Achieves a Significant Milestone in the Development  of Camelina as a Commercial Crop for Producing Biofuels and Omega-3 Oils

USDA-APHIS Determines that Yield10 Bioscience's Glufosinate Tolerant Camelina May Be Planted and Bred in the United States

Yield10 Bioscience, Inc. (NASDAQ:YTEN ) Q3 2023 Earnings Conference Call November 14, 2023 4:30 PM ET Company Participants Lynne Brum - Investor Relations Oliver Peoples - President and Chief Executive Officer Kristi Snell - Vice President, Research and Chief Science Officer Chuck Haaser - Chief Accounting Officer Conference Call Participants Ben Klieve - Lake Street Capital Markets Noel Parks - Tuohy Brothers Operator Hello and welcome to the Third Quarter 2023 Financial Results and Business Update Conference Call for Yield10 Bioscience. [Operator Instructions] As a reminder, this conference call is being recorded.

Yield10 Bioscience, Inc. (YTEN) Q3 2023 Earnings Call Transcript

-Establishes "Camelina Seed Genetics to Biofuel" Platform -Advances Herbicide Tolerant Camelina Varieties toward Commercialization -Exercises Option to Finalize Exclusive, Global Commercial License to Advanced Omega-3 Technology -Management will host a conference call today at 4:30 pm (ET)

Yield10 Bioscience Announces Third Quarter 2023 Financial Results

WOBURN, Mass., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Yield10 Bioscience, Inc. (Nasdaq:YTEN) (“Yield10” or the “Company”), an agricultural bioscience company, today announced that the Company will report its third quarter 2023 financial results and provide a corporate update on Tuesday, November 14, 2023.

Yield10 Bioscience to Announce Third Quarter 2023 Financial Results and Host a Conference Call on Tuesday, November 14, 2023

Yield10 Bioscience and BioMar Group have signed an LOI to form a long-term partnership to commercialize a Camelina crop containing enriched levels of EPA and DHA equal to fish oil. After a decade of research, this Omega-3 Camelina technology is now advancing toward market availability and has the potential to become another important, high-quality supplement to the scarce supply of marine long-chain fatty acids.

Yield10 Bioscience and BioMar Aim to Grow Fish Oil on Land

Farmer Bros.

Red Robin

Focusing on small cap stocks and emphasizing the importance of admitting you're wrong. Farmer Brothers, Red Robin Gourmet Burgers, and Yield10 Bioscience examples of small cap stocks with potential.

Courage & Conviction Investing On Farmer Bros, Red Robin And Yield10 Bioscience

WOBURN, Mass., Oct. 18, 2023 (GLOBE NEWSWIRE) -- Yield10 Bioscience, Inc. (Nasdaq:YTEN) (“Yield10” or the “Company”), an agricultural bioscience company, today announced that the Company has exercised its option to finalize an exclusive global, commercial license to advanced omega-3 production technology from U.K.-based Rothamsted Research Limited (“Rothamsted”). In 2020, Yield10 signed an exclusive collaboration agreement with Rothamsted to support Rothamsted's Flagship Program to develop omega-3 oils in Camelina sativa (“Camelina”). As part of the collaboration agreement, Yield10 received an exclusive option to sign a global, exclusive license agreement for the technology.

Yield10 Bioscience Exercises Option to Finalize an Exclusive, Global Commercial License to Advanced Omega-3 Camelina Technology from Rothamsted Research

-On track for commercial launch of first herbicide tolerant Camelina variety as early as 2025 -First field tests of stacked herbicide tolerant winter Camelina underway -Recent positive field tests demonstrate stacked herbicide traits in spring Camelina -Herbicide tolerance in Camelina supports large acreage production of low-carbon intensity feedstock oil for the biofuel market WOBURN, Mass., Oct. 11, 2023 (GLOBE NEWSWIRE) -- Yield10 Bioscience, Inc. (Nasdaq: YTEN) (“Yield10” or the “Company”), an agricultural bioscience company, today announced recent advancements toward enabling weed control for Camelina cultivation and supporting grower adoption of the crop for production of low-carbon intensity feedstock oil for the biofuel market.

Yield10 Bioscience Provides Update on Recent Advancements in the Development of Elite Herbicide Tolerant Camelina

Begins revenue generation for “Camelina Seed Genetics to Biofuel” platform Begins revenue generation for “Camelina Seed Genetics to Biofuel” platform

Yield10 Bioscience Completes Harvest of a Majority of the 2023 Winter and Spring Camelina Grain Grown Under Contract, Generating Revenue from Biofuel Production

Advanced Emissions Solutions

Courage & Conviction Investing discusses why small cap investors should stay committed and have conviction in their ideas despite market drawdowns. Why he's never been more bullish on Advanced Emissions Solutions.

'Stay Hungry, Stay Foolish' Small Cap Strategies With Courage & Conviction Investing

WOBURN, Mass., Sept. 07, 2023 (GLOBE NEWSWIRE) -- Yield10 Bioscience, Inc. (Nasdaq: YTEN) (“Yield10” or the “Company”), an agricultural bioscience company, today announced that management will participate in the H.C. Wainwright 25th Annual Global Investment Conference being held on September 11-13, 2023, at the Lotte New York Palace Hotel.

Yield10 Bioscience to Present at the H.C. Wainwright 25th Annual Global Investment Conference

WOBURN, Mass., Aug. 15, 2023 (GLOBE NEWSWIRE) -- Yield10 Bioscience, Inc. (Nasdaq:YTEN) (“Yield10” or the “Company”), an agricultural bioscience company, today announced the closing of its previously announced public offering of 5,750,000 units at a public offering price of $0.65 per unit. Each unit consisted of one share of common stock and one warrant to purchase one share of common stock. The warrants are immediately exercisable at an exercise price of $0.65 per share and expire five years from the date of issuance. The shares of common stock and accompanying warrants could only be purchased together in this offering but were issued separately and are immediately separable upon issuance.

Yield10 Bioscience Announces Closing of $3.7 Million Public Offering

Yield10 Bioscience, Inc. (NASDAQ:YTEN ) Q2 2023 Earnings Conference Call August 14, 2023 4:30 PM ET Company Participants Lynne Brum – Vice President of Planning and Corporate Communications Oli Peoples – Chief Executive Officer Kristi Snell – Vice President of Research and Chief Science Officer Chuck Haaser – Chief Accounting Officer Conference Call Participants Anthony Vendetti – Maxim Group Operator Welcome to the Second Quarter 2023 Financial Results and Business Update Conference Call for Yield10 Bioscience. During the call, participants will be in a listen-only mode.

News for Yield10 Bioscience Stock (YTEN)